death [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Consequently, compensated and decompensated liver cirrhosis are common occurrences in these patients.
The evolution of compensated HCV-related cirrhosis in monoinfected patients is slow and can be accelerated by alcohol abuse, hepatitis B virus (HBV) infection, and metabolic disorders [12] [13] [14] . Therapy against HCV can delay the development of liver-related clinical events in HCV-monoinfected patients [15] . The incidence of liver complications in large cohorts of HCV-monoinfected subjects is low, with annual rates of clinical decompensation 3%-7% and of liver-related mortality 2%-3% [12] [13] [14] 16] .
Although the outcome of decompensated cirrhosis in HIV-HCV-coinfected subjects is well known [7] [8] [9] [10] 17] , the few reported studies on compensated cirrhosis have analyzed low sample sizes or have dealt only slightly with predictors of clinical outcome [18, 18] . Because of the effect of HIV coinfection on the natural history of HCV-related liver disease [19] [20] [21] and specifically on the outcome of decompensated liver cirrhosis [7] , shorter times to decompensation and death are expected, but this should be confirmed. More information about the clinical outcome of compensated cirrhosis is critically needed to define better therapy interventions for end-stage liver disease in coinfected patients. Because of this, we obtained data about the clinical outcome of compensated HCV-related cirrhosis in HIV-infected patients and analyzed the predictors of liver decompensation and death due to liver failure.
METHODS

Patients and follow-up.
From January 1996 through September 2006, a cohort of 2754 HIV-HCV-coinfected individuals was prospectively followed at 7 hospitals in southern Spain. All the patients from this cohort who fulfilled the following inclusion criteria were analyzed: (1) detectable plasma HCV-RNA at enrollment, (2) diagnosis of Child-Pugh-Turcotte (CPT) class A cirrhosis made for the first time at or after enrollment in the cohort, and (3) no decompensation of liver disease before entering the cohort. Subjects who presented with a liver decompensation at the time of cirrhosis diagnosis were excluded. Patients were followed up until death, loss to follow-up, liver transplantation, or the censoring date (30 September 2006) . Visits were scheduled at least every 6 months. A clinical, virologic, immunologic, and biochemical evaluation was performed at every visit. Liver disease was managed primarily by specialists in infectious diseases, in accordance with protocols stated elsewhere [1, 7, 8] .
Alcohol intake was assessed by patient interview. In patients who received a blood transfusion or who used intravenous drugs, the duration of HCV infection was estimated as the time from the first blood transfusion or the first year sharing needles to the diagnosis of cirrhosis.
Antiretroviral therapy was prescribed in each visit in accordance with the recommendations of international guidelines. Combinations included nucleoside analogues, protease inhibitors, nonnucleoside retrotranscriptase inhibitors (NNRTI), and entry inhibitors.
Diagnostic criteria. The diagnosis of liver cirrhosis could be based on either histology, transient elastography (TE), or combined clinical, laboratory, and ultrasound imaging data. Liver biopsy that showed fibrosis stage 4, according to the Scheuer scoring system [22] , was diagnostic of cirrhosis. A hepatic stiffness у14.6 kPa measured by TE (Fibroscan; Echosens) was considered to be indicative of cirrhosis. This cut-off value has shown high accuracy in discriminating cirrhosis in studies in both HCVmonoinfected and HIV-HCV-coinfected patients [23] [24] [25] [26] . Finally, patients were classified as cirrhotic if they showed clinical, laboratory, and ultrasound imaging data consistent with cirrhosis. Clinical data suggestive of cirrhosis were skin vascular collaterals, hepatomegaly, splenomegaly, jaundice, palmar erythema, vascular spiders, gynecomastia, and testicular atrophy. Laboratory findings that supported cirrhosis were thrombocytopenia, prolonged serum prothrombin time, bilirubin elevation, hypergammaglobulinemia, aspartate and alanine aminotransferase elevations, serum albumin reduction, and cholinesterase reduction. Ultrasound images that suggested cirrhosis were a small nodular irregular liver, hypertrophy of the caudate lobe, and/or indirect signs of portal hypertension.
The model for end-stage liver disease (MELD) score was calculated using the following formula: 3.8Lnbilirubin + 9.6Lncreat-inine + 11.2LnINR + 6.4 [27] .
We considered that cirrhosis became decompensated when one of the following disorders emerged: ascites, upper gastrointestinal bleeding secondary to varices or portal hypertensive gastrointestinal bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatocellular carcinoma, nonobstructive jaundice, and hepatic encephalopathy (HE). The diagnostic procedures used for each of these complications have been stated elsewhere [1, 7, 8] .
Laboratory methods. Serum HCV antibodies were detected by enzyme immunoassay (EIA) (Ortho Diagnostic System). HCV-RNA was tested by either qualitative polymerase chain reaction (PCR) ( The development of the first episode of hepatic decompensation and death due to liver failure were the primary end points. The relationship between the time to the emergence of these end points and the following variables was analyzed: sex, baseline age, age at HCV infection, estimated length of HCV infection, way of HCV infection, HCV genotype, HBV and HDV coinfections, Centers for Disease Control and Prevention clinical stage, plasma HIV viral load, CD4 cell counts, alanine aminotransferase elevations, bilirubin, platelets, g-glutam-yltranspeptidase, serum prothrombin time, MELD score, CPT score 5 or 6, self-reported daily alcohol consumption, procedure of diagnosis of cirrhosis, use of therapy against HCV, and antiretroviral therapy during the follow-up.
The baseline time point was considered to be the date of diagnosis of cirrhosis. The time-to-event was calculated as the months elapsed from this time point to the different end points. Estimated survival functions were calculated using the KaplanMeier method, and survival curves were compared by the logrank test. Continuous variables were categorized in these analyses according to the median or cut-off points that were considered clinically relevant. Covariates with on bivar-P р .1 iate analysis were introduced in a Cox regression model. To deal with the competing risk of the different causes of mortality, we performed Cox regressions that stratified by causes of death (hepatic or other). Thus, each stratum was allowed to have its own baseline hazard function, but we restricted the coefficients to be the same across data.
The statistical analysis was performed using the SPSS 14.0 statistical software package (SPSS) and the Stata 9 SE package (StataCorp).
Ethical aspects. The study was designed and performed in accordance with the Declaration of Helsinki and was approved by the ethics committee of each participating hospital.
RESULTS
Characteristics of the study population.
One hundred and fifty-four HIV-HCV-coinfected patients with CPT class A compensated cirrhosis were analyzed in this study. The most relevant characteristics of this population are shown in Table 1 . The mean follow-up time (‫ע‬standard deviation) was 36 ‫ע‬ 27 months (range, 1-131 months). During this period, only one patient underwent a liver transplant, and 14 patients (9%) were lost to follow-up. Fifteen patients (9.7%) showed an episode of hepatotoxicity during the follow-up.
Forty-four patients (28.6%) were not receiving highly active antiretroviral therapy (HAART) at baseline. Thirty-five (79.5%) of these 44 patients started receiving HAART during the followup. Protease inhibitor-based combinations were the most commonly used HAART strategy. Seventy-two patients (46.8%) received a protease inhibitor-based combination throughout the follow-up. Thirty-six patients (23.4%) were receiving NNRTIincluding combinations during the entire follow-up, and 29 patients (18.8%) were switched from a protease inhibitor-based HAART to an NNRTI-based HAART or vice versa. Eight individuals (5.2%) received other HAART combinations.
Incidence of hepatic decompensation. Thirty-six patients (23.4%) developed a first hepatic decompensation during the follow-up. The density of incidence of first hepatic decompensations was 6.40 cases per 100 person-years (95% confidence interval [CI], 4.18-9.38 cases per 100 person-years). The probability of developing decompensated cirrhosis at 3 years was 26% (95% CI, 19%-36%) and at 5 years was 33% (95% CI, 24%-45%). Eighteen (50%) of these 36 patients developed ascites as the first manifestation of end-stage liver disease. HE was observed in 6 patients (17%), portal hypertensive gastrointestinal bleeding in 6 (17%), hepatocellular carcinoma in 3 (8%), and jaundice in 3 (8%). Factors associated with the occurrence of a first hepatic decompensation in the bivariate analysis are shown in Table 2 . Clinical diagnosis of cirrhosis ( Figure 1A ), no HCV therapy during the follow-up ( Figure 1B ), lower CD4 cell counts, and higher CPT score were independently associated with decompensation of liver disease ( Table 2 ). The probability of developing a hepatic decompensation at 3 years among patients with CPT score 5 was 13% (95% CI, 7%-23%) and among patients with CPT score 6 was 63% (95% CI, 44%-81%). The probability of developing a hepatic decompensation at 5 years among patients with CPT score 5 was 19% (95% CI, 11%-33%) and among patients with CPT score 6 was 71% (95% CI, 51%-88%). No antiretroviral drug, drug family, or strategy was associated with the emergence of hepatic decompensation.
Survival and causes of death. Fifteen patients (9.7%) died during the follow-up. The overall mortality rate was 3.32 deaths per 100 person-years (95% CI, 1.86-5.48 deaths per 100 personyears). Eleven individuals (73%) died because of liver failure. The mortality rate due to liver failure was 2.44 deaths per 100 person-years (95% CI, 1.21-4.36 deaths per 100 person-years). The probability of death from liver disease at 3 years was 6% (95% CI, 3%-14%), and the probability of death from liver disease at 5 years was 13% (95% CI, 7%-25%). Only one patient died because of AIDS. The causes of death in the remaining 3 patients were lung cancer, chronic obstructive pulmonary disease, and acute pancreatitis. Among the 11 patients who died because of liver-related disease, HE was the cause of death in 9 patients (82%), portal hypertensive gastrointestinal bleeding in 1, and hepatocellular carcinoma in 1.
Factors that predicted mortality from liver disease in the univariate analysis are shown in Table 3 . HE as the first decompensation, lower baseline CD4 cell counts, and higher baseline CPT score were independently associated with mortality due to liver failure ( Table 3 ). The probability of death of patients with CPT score 5 at 3 years was 3% (95% CI, 1%-11%) and at 5 years was 6% (95% CI, 2%-20%), whereas the probability of death of patients with CPT score 6 at 3 years was 17% (95% CI, 3%-33%) and at 5 years was 35% (95% CI, 16%-67%). Again, there was no association between anti-HIV therapy and liver-related mortality.
DISCUSSION
The clinical outcome of CPT class A compensated cirrhosis in HIV-HCV-coinfected patients in this study was better than expected. In fact, it has been estimated that HIV coinfection entails a 6-fold increase of the risk of HCV-related decompensated liver disease [11] . In addition, the relative risk of death in HIV-HCV-coinfected patients with decompensated cirrhosis is 2.26 (95% CI, 1.51-3.38), in relation to HCV-monoinfected patients [7] . However, in this study the rate of events in HIV-HCV-coinfected patients with compensated cirrhosis was not far from that reported in HCV-monoinfected population. In fact, the overall mortality after 5 years of follow-up in a French cohort of monoinfected patients was 15.35% [28] . Similarly, the annual rate of mortality was 4% in an Italian study [13] , and the frequency of liver-related deaths was 18.6% after a median follow-up of about 8 years in another study [14] . These values are close to those observed in this study. The rates of decompensation reported in 2 cohorts of HCV-monoinfected patients with compensated cirrhosis have been lower than those found here, specifically 18% at 5 years [12] and 32% at 8 years [14] . However, in another report, the annual incidence of decompensations was very similar to that reported here, 6.9% [13] . A number of facts may have accounted for an incidence of liver events lower than expected in this study. First, many patients in this study received HAART during the follow-up. HAART use has been associated with an improvement of the clinical outcome of patients with HIV-HCV coinfection [10, 18, 29, 30] . Second, 43% of patients received therapy against HCV infection, a predictor of better outcome. Third, 70% of patients were diagnosed with compensated cirrhosis by biopsy or TE. Cirrhosis is detected earlier with these procedures, and these ways of diagnosing have been associated with a lower risk of decompensation in this study. Indeed, studies that showed a much higher risk of decompensation [11] or death [7, 11] in coinfected patients were performed when HAART, HCV therapy, and procedures for early diagnosis were less common, which may explain the differences.
Previous data with regard to compensated cirrhosis in HIV-HCV-coinfected patients are limited and are based on small populations [17, 18] . The results in this report are similar to data from another Spanish cohort: the probability of developing decompensated cirrhosis at 1 year was 10% and at 2 years was 14% in that cohort [17] , and the probability at 1 year was 8% and at 2 years was 18% in the present study (data not shown). On the other hand, the survival estimate at 5 years was 71.5% in an Italian cohort [18] , lower than that observed in this study. However, in that study only 58% of patients were receiving HAART [18] , whereas 95% of patients included in this study received HAART. The lower rate of HAART use in the Italian cohort may explain survival estimates different from those of our study.
The main limitation of this study is that a control group of HCV-monoinfected patients was not included, which led us to compare our data with those of patients previously studied in other areas and at different times. Thus, different rates of HCV therapy use, diverse diagnostic procedures, and differences in alcohol or drug use might have impacted our findings. However, the results of this study were similar to those found in others performed with HIV-HCV-coinfected patients [17] . Likewise, data on the clinical outcome in HCV-monoinfected patients with compensated cirrhosis have also been relatively uniform [12] [13] [14] 28] . This fact leads us to believe that the compensated cirrhosis outcome of HIV-HCV-coinfected patients is actually not very different from that observed in HCVmonoinfected patients. Another limitation is that the followup period was relatively short, and the number of events, particularly deaths due to liver failure, was low. This might have prompted multivariate models to be overfitted. Accordingly, predictors of clinical outcome, especially deaths, might not be accurate. Nevertheless, the predictors of poor evolution reported herein are consistent with those found in prior studies in coinfected patients [1, 7, 10, 17] . The sample size, which to our knowledge is the largest analyzed so far with a very specific condition such as CPT class A compensated cirrhosis in HIV-HCV-coinfected patients, is a strength of this study that counteracts in part the former limitations. In addition, in prior studies on compensated cirrhosis in HIV-HCV-coinfected patients, the analysis of predictors of outcome was very limited or absent [17, 18] . Because of this, the present study adds substantial new information on this issue. Survival was shortened in individuals with markers of endstage liver disease, such as HE and higher CPT score. Remarkably, the probability of developing decompensation and death was higher for patients with CPT score 6 than for patients with CPT score 5. Thus, minimal changes in this score are very relevant for prognosis. Likewise, this finding supports the high reliability of this score in HIV-HCV-coinfected cirrhotics, where it seems to be superior to the MELD score, at least in the long term [10, 17] . High alcohol intake tended to be related with hepatic decompensation. The unreliability of self-reported alcohol consumption might have precluded significant association with liver outcomes. Baseline CD4 cell counts !300/ mm 3 and CD4 percentage !15% were associated with both decompensations and liver-related death. Low CD4 counts were associated with liver mortality in HIV-HCV-coinfected patients with decompensated cirrhosis [10] and in the overall coinfected population [29, 30] . These data support the idea that HIV-HCV-coinfected patients with compensated liver cirrhosis should start receiving HAART with higher CD4 cell counts to prevent immune devastation, reduce systemic inflammation and immune activation [31, 32] , and thus decrease liver disease progression. HCV therapy during the follow-up was associated with a lower incidence of liver decompensation in our study. These data agree with data observed in HCV-monoinfected compensated cirrhotics, for whom anti-HCV therapy delays the development of liver events [15] , and with data observed in the overall HIV-HCV-coinfected population, for whom response to treatment of HCV infection leads to better hepatic outcomes [1, 33] . Finally, an improved hepatic outcome might have been expected in patients who were receiving HAART during the follow-up, according to previous observations in HIV-HCV-infected cohorts who were receiving HAART [10, 29, 30] . However, only a few patients in this study were not on HAART during the follow-up. For these reasons, a positive effect of HAART on liver outcomes was not observed.
We observed different evolutions for patients diagnosed with cirrhosis by TE or biopsy and those diagnosed by the combination of clinical, laboratory, and ultrasound imaging data. This could be because of the earlier diagnosis of cirrhosis by means of TE or biopsy. An earlier diagnosis may lead to earlier implementation of programs designed to prevent major complications. In the past years, TE has been shown to be highly reliable for the diagnosis of cirrhosis in HCV-monoinfected and HCV-HIV-coinfected patients [23] [24] [25] [26] . The use of this procedure can make an early detection of asymptomatic patients with cirrhosis easier in the future.
In summary, this study shows that the clinical outcome of HIV-infected patients with compensated HCV-related cirrhosis who are receiving HAART is not much worse than that observed in HCV-monoinfected patients, a finding that is unlike those of studies of patients with decompensated liver disease. In addition, survival at this stage is much longer than when decompensations emerge [7-10, 17, 18] . This fact should prompt us to undertake therapeutic interventions at this stage, because therapy against HCV is associated with lower incidence of decompensation. On the other hand, an earlier start of HAART may yield benefits on the evolution of liver disease in HIV-HCV-coinfected patients with compensated cirrhosis, because low CD4 cell counts are a predictor of poor outcome.
Finally, sequential measurements of liver stiffness by TE may lead to an earlier diagnosis of cirrhosis that allows us to implement measures to prevent complications of liver disease earlier than we currently do.
